Life Sciences Market Research Reports

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 13 Aug 2024  |  Global  |  Frost Radar

    Frost Radar : Healthcare Data Interoperability, 2024

    A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

    This Frost Radar benchmarks companies and their solutions that enable the exchange and use of data between healthcare applications. Interoperability improves continuity of care, increases communication and connectivity between different stakeholders (e.g., payors, providers, patients, public health bodies), and reduces inefficiencies. Organizat...

    $4,950.00
  2. 12 Aug 2024  |  Global  |  Frost Radar

    Frost Radar : Laboratory Information Management Systems, 2024

    A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

    This Frost Radar for the laboratory information management systems (LIMS) industry benchmarks providers offering workflow management and paperless tracking capabilities to help improve process efficiencies for life sciences companies. LIMS have several functionalities, such as obtaining, storing, managing, retrieving, and recording laboratory data...

    $4,950.00
  3. 25 Apr 2024  |  Global  |  Frost Radar

    Frost Radar : Healthcare Enterprise Managed Cloud Services, 2024

    A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

    In the cloud industry and most other technology-related industries, 2024 will be all about artificial intelligence (AI). Businesses are grappling with how they can leverage AI (particularly generative AI) to meet their goals. Public cloud providers are at the forefront of efforts to accelerate customers AI adoption by developing foundational model...

    $4,950.00
  4. 30 Mar 2023  |  North America  |  Customer Research

    Global Laboratory Product Purchasing Trends, 2022–2023

    End–user Perspectives on Laboratory Spending Reveals Modest 2023 Budget Increases Following robust 2022 Spending

    Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey from October to November 2022 examining their laboratories’ product purchasing process in 2022 and expectations for 2023. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. The study presents year-o...

    $4,950.00
  5. 16 Nov 2022  |  North America  |  Frost Radar

    Frost Radar™: Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022

    A Benchmarking System to Spark Companies to Action-Innovation that Fuels New Deal Flow and Growth Pipelines

    As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

    $4,950.00
  6. 23 Aug 2022  |  North America  |  Frost Radar

    Frost Radar™: US Liquid Biopsy, 2022

    A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

    The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...

    $4,950.00
  7. 28 Oct 2013  |  Global  |  Customer Research

    Competing in the Global Contract Manufacturing Market

    What Pharmaceutical and Biotechnology Companies Want and How to Compete for their Business

    The overall objective of this study was to provide contract manufacturing organizations (CMOs) a sound basis for formulating an effective strategy to compete in the market, including areas of opportunities and threats. As far as the market dynamics and CMO selection are concerned, overall satisfaction and likelihood of contract renewal are in the 4...

    $10,000.00
  8. 02 Sep 2013  |  North America  |  Customer Research

    Global Analysis of MicroRNA Tools and Services Market

    Evolving microRNA Market Provides an Opportunity for Vendors of qRT-PCR and Functional Tools

    The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house NGS technology use is expected to increase within the next 12 months. Data accuracy and operating costs are the top criteria for purchasing sequencing instruments. Disease-r...

    $10,000.00